Access to Excellence: Montana Cancer Consortium CCOP (MCC) has since 1996 provided access to NCI sponsored clinical trials for all 46 medical and radiation oncologists in Montana and Northern Wyoming, serving approximately 1 million people in a rural area of 150,000 square miles. Montana health care quality ranks among the highest in the country, but access to care ranks low due to the vastness of the region and concentration of the medical community in a few widespread cities. MCC membership includes 22 affiliate performance sites. As our physicians work to access the population through outlying clinics hundreds of miles from home, MCC provides access to state-of-the-art cancer treatment and control via cutting-edge research of NCI-sponsored trials. This uniquely rural population including 7 Native American reservations does not have convenient access to large university-based treatment facilities, and without nationally recognized clinical trials, patients would not have access to a high level of cancer care. MCC intends to extend access by expanding the physician roster to include other disciplines. Accrual: MCC is currently affiliated with 4 research bases, SWOG, NSABP, NCCTG, and RTOG as well as CTSU. MCC is actively pursuing a fifth affiliation to increase access to cancer control and prevention trials. MCC ranks high in accrual with the research bases accruing more than 4000 participants to clinical trials. The goal is to increase accrual by 5% annually. Quality: MCC is dedicated to quality data and maintains excellent performance reviews and audits. Centralized data management and quality assurance ensure timely registrations and submissions of data. Human subject protection is achieved by central IRB review. Drug accountability is met by a central pharmacy (Billings) and supervised satellites. The goal of MCC is to maintain and enhance this level of quality through education and increased communication. The uniquely rural population of Montana and Northern Wyoming lacks convenient access to large university-based treatment facilities and without nationally-recognized clinical trials patients would not have access to a high level of cancer care. MCC provides access to state-of-the-art cancer treatment and cancer control through cutting edge research of NCI-sponsored clinical trials.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA067575-18
Application #
8308656
Study Section
Special Emphasis Panel (ZCA1-SRRB-Y (J1))
Program Officer
O'Mara, Ann M
Project Start
1995-09-18
Project End
2013-05-31
Budget Start
2012-06-01
Budget End
2013-05-31
Support Year
18
Fiscal Year
2012
Total Cost
$412,534
Indirect Cost
Name
Montana Cancer Consortium
Department
Type
DUNS #
802713917
City
Billings
State
MT
Country
United States
Zip Code
59101
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7
Kernstine, Kemp H; Moon, James; Kraut, Michael J et al. (2014) Trimodality therapy for superior sulcus non-small cell lung cancer: Southwest Oncology Group-Intergroup Trial S0220. Ann Thorac Surg 98:402-10
Erba, Harry P; Othus, Megan; Walter, Roland B et al. (2014) Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432. Leuk Res 38:329-33
Flaherty, Lawrence E; Othus, Megan; Atkins, Michael B et al. (2014) Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Ch J Clin Oncol 32:3771-8
Bepler, Gerold; Zinner, Ralph G; Moon, James et al. (2014) A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701). Cancer 120:2343-51
Deininger, Michael W; Kopecky, Kenneth J; Radich, Jerald P et al. (2014) Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia. Br J Haematol 164:223-32
Allen, Jeffrey W; Moon, James; Redman, Mary et al. (2014) Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer. J Clin Oncol 32:2463-70
Philip, Philip A; Goldman, Bryan; Ramanathan, Ramesh K et al. (2014) Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWO Cancer 120:2980-5
Coleman, Robert L; Moon, James; Sood, Anil K et al. (2014) Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904. Eur J Cancer 50:1638-48
Goldkorn, Amir; Ely, Benjamin; Quinn, David I et al. (2014) Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol 32:1136-42

Showing the most recent 10 out of 123 publications